随访间隔对类风湿关节炎疾病控制的性别特异性影响:中国15835例全国分析
女性起病更年轻、病程更长、低疾病活动度/临床缓解率更高、糖皮质激素使用更少;两性随访间隔>3个月均常见。延长随访间隔仅在女性亚组独立关联疾病控制不佳(CDAI>10),但性别交互作用不显著,提示为描述性趋势而非验证的性别差异。
要点
- 女性RA患者起病更年轻、病程更长、缓解率更高、激素使用更少。
- 两性随访间隔>3个月均常见(女性61.30%,男性62.65%)。
- 延长随访间隔仅与女性疾病控制不佳独立相关,但性别交互作用不显著。
核心结论
- 延长随访间隔仅在女性RA亚组中独立关联疾病控制不佳(CDAI>10),但性别与随访间隔的交互作用不显著,提示为描述性趋势而非验证的性别特异性差异。
主要发现
- 女性较男性起病更年轻(45.84 vs 51.03岁,P<0.001)、病程更长(7.51 vs 5.64年,P<0.001)、低疾病活动度/临床缓解率更高(22.61% vs 15.33%,P<0.001)、糖皮质激素使用更少(39.5% vs 47.73%,P<0.001)。
- 两性自报规律随访率相似(84.73% vs 83.14%),但随访间隔>3个月者分别达61.30%和62.65%(P<0.001)。
- 在女性亚组中,延长随访间隔独立关联疾病控制不佳(CDAI>10),6个月间隔OR=1.22(95%CI 1.09-1.37,P<0.001),12个月间隔OR=1.43(95%CI 1.22-1.60,P<0.001)。
- 规律监测降低两性高疾病活动度风险(OR=0.64,95%CI 0.56-0.74,P<0.001)。
- 广义线性模型显示随访间隔与性别对疾病活动度无显著交互作用(所有P>0.20)。
关键数值与推荐
- 疾病活动度采用CDAI评估,疾病控制不佳定义为CDAI>10。
- 随访间隔延长与女性疾病控制不佳的关联:6个月间隔OR=1.22(95%CI 1.09-1.37,P<0.001),12个月间隔OR=1.43(95%CI 1.22-1.60,P<0.001)。
- 规律监测降低高疾病活动度风险:OR=0.64(95%CI 0.56-0.74,P<0.001)。
临床怎么用
- 应关注RA患者随访间隔,尤其女性患者延长随访间隔可能提示疾病控制不佳风险。
- 规律监测与两性较低的高疾病活动度风险相关,应优化照护连续性。
- 性别二态性趋势提示制定策略时需考虑性别差异以改善RA管理。
局限性
- 性别与随访间隔的交互作用不显著,interval-dependent疾病控制趋势为描述性,非验证的性别特异性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Previous studies have identified unique challenges for RA patients of different genders, which impact disease management. However, the association between disease activity and health-care-seeking behaviours in male and female RA patients remains underexplored. This study aimed to investigate this association, with a specific focus on the gender-specific effects of follow-up intervals on disease control. METHODS: A nationwide survey (July-September 2023) across 330 rheumatology centres in China included 13 278 female (83.85%) and 2557 male RA patients (16.15%) aged ≥18 years. Standardized questionnaires captured demographic and health-care-seeking behaviours. Disease activity was assessed using the Clinical Disease Activity Index (CDAI). RESULTS: Females had younger disease onset (45.84 vs 51.03 years, P < 0.001), longer disease duration (7.51 vs 5.64 years, P < 0.001), higher low disease activity/clinical remission rates (22.61% vs 15.33%, P < 0.001), and lower glucocorticoid use (39.5% vs 47.73%, P < 0.001). Despite similar self-reported regular follow-up rates (84.73% vs 83.14%), both genders experienced suboptimal visit intervals (>3 months: 61.30% vs 62.65%, P < 0.001). Prolonged follow-up intervals were independently associated with poor disease control (CDAI > 10) in the female subgroup, with longer intervals linked to higher odds of inadequate control at 6-month [odds ratio (OR) = 1.22, 95% CI: 1.09-1.37, P < 0.001] and 12-month intervals (OR = 1.43, 95% CI: 1.22-1.60, P < 0.001). Regular monitoring reduced high disease activity risk across genders (OR = 0.64, 95% CI: 0.56-0.74, P < 0.001). A generalized linear model showed no significant follow-up interval - gender interaction on disease activity (all P > 0.20). CONCLUSION: This large-scale study revealed gender-dimorphic patterns in RA progression and health-care engagement. Females tended to exhibit better treatment response, with a more pronounced interval-dependent disease control trend. No significant interval-gender interaction confirmed this was a descriptive trend, not a validated gender-specific difference. Our findings emphasize the need for strategies accounting for such gender-dimorphic trends to optimize care continuity and improve RA management.
引用
- Xu H, Zhang L, Huo Y, et al. Gender-specific impact of follow-up intervals on disease control in rheumatoid arthritis: a nationwide analysis of 15 835 Chinese patients. Rheumatology (Oxford). 2026. PMID: 41649470. doi:10.1093/rheumatology/keag079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。